Multinational drugmaker Novartis India's profit after tax stood at Rs 32 crore, for the three months ended March 31, 2012, compared with Rs 34 crore in the corresponding period of the previous year.
The company clocked Rs 204 crore as its income from operations, a growth of about 12 per cent over the corresponding previous quarter.
Its core pharmaceutical business recorded net sales from operations of Rs 139 crore in the period under review, against Rs 123 crore in the corresponding period last year. The generic drugs business recorded net sales of Rs 14 crore (Rs 15 crore). Its over-the-counter business registered a net sales of Rs 29 crore (Rs 26 crore) and the animal health business registered net sales of Rs 22 crore (Rs 18 crore).
An unprecedented downward spiral in the value of the rupee impacted the financial results of the year under review.
For the 12 months ended March 31, 2012, Novartis clocked an income from operations of Rs 844 crore, an increase of 12 per cent over last year's income of Rs 751 crore. Profit after tax stood at Rs 152 crore against Rs 146 crore during the previous comparable period.
The company's core pharmaceuticals business registered net sales of Rs 586 crore (Rs 523.9 crore). The generics business recorded net sales of Rs 57 crore (Rs 55.4 crore). Its OTC business registered revenues of Rs 117 crore (Rs 101 crore) and the animal health business recorded an income from operations of Rs. 83 crore (Rs 70.7 crore), a company statement said.
Novartis shares were marginally up on the BSE at Rs 719 on Thursday.